In the univariate analysis which included age, gender, histological diagnosis, smoking status, ECOG, central nervous system metastases, clinical type, treatment line of crizotinib therapy, clinical stage, oncogenes, tumor-suppressor genes and ALK variants, we found that smoking status (P = 0.048), treatment line of crizotinib therapy (P = 0.047), oncogenes (P = 0.0003) and tumor-suppressor genes (P = 0.0031) were significantly associated with PFS. This evidence concerns the gene ALK and neoplasm.